Current Concepts in Management of Vestibular Schwannomas in Neurofibromatosis Type 2 (original) (raw)

Natural History of Vestibular Schwannoma Growth and Hearing Decline in Newly Diagnosed Neurofibromatosis Type 2 Patients

Vanessa Merker

Otology & Neurotology, 2014

View PDFchevron_right

A clinical study of vestibular schwannomas in type 2 neurofibromatosis

Ameet Kishore

Clinical Otolaryngology and Allied Sciences, 2000

View PDFchevron_right

Vestibular Schwannoma Excision in Sporadic versus Neurofibromatosis Type 2 Populations

Yaser Ghavami

Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2015

View PDFchevron_right

Gamma Knife radiosurgery for treatment of growing vestibular schwannomas in patients with neurofibromatosis Type 2: a matched cohort study with sporadic vestibular schwannomas

Patrick Hanssens

Journal of Neurosurgery, 2017

View PDFchevron_right

Bevacizumab Treatment for Vestibular Schwannoma in a Patient with Neurofibromatosis Type 2: Hearing Improvement and Tumor Shrinkage

David Rondonotti

Tumori Journal, 2015

View PDFchevron_right

A systematic review of radiosurgery versus surgery for neurofibromatosis type 2 vestibular schwannomas

Thiên Phước Nguyễn

World neurosurgery, 2017

View PDFchevron_right

Bevacizumab in Neurofibromatosis type 2 (NF2) related vestibular schwannomas: a nationally coordinated approach to delivery and prospective evaluation

Rosalie Ferner

Neuro-Oncology Practice, 2016

View PDFchevron_right

Bevacizumab for Progressive Vestibular Schwannoma in Neurofibromatosis Type 2

Vanessa Merker

Otology & Neurotology, 2012

View PDFchevron_right

Tumor control and hearing preservation after Gamma Knife radiosurgery for vestibular schwannomas in neurofibromatosis type 2

Manish Sharma

Journal of Neuro-Oncology, 2010

View PDFchevron_right

Three-Fraction Stereotactic Radiosurgery for Treatment of Vestibular Schwannoma (Acoustic Neuroma) in Patients with Neurofibromatosis Type 2

John Adler

Journal of Radiosurgery, 1999

View PDFchevron_right

Evidence of polyclonality in neurofibromatosis type 2-associated multilobulated vestibular schwannomas

John Butman

Neuro-oncology, 2014

View PDFchevron_right

Fractionated stereotactic radiotherapy for bilateral vestibular schwannomas associated with neurofibromatosis type 2: early experiences in Ramathibodi Hospital

Pornpan Yong

Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2004

View PDFchevron_right

Progress of hearing loss in neurofibromatosis type 2: implications for future management

Simon Freeman

European Archives of Oto-Rhino-Laryngology, 2014

View PDFchevron_right

Linear accelerator radiosurgery for treatment of vestibular schwannomas in neurofibromatosis 2

Daniel Roos

Journal of Clinical Neuroscience, 2008

View PDFchevron_right

Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2

Rosalie Ferner

American Journal of Medical Genetics Part A, 2012

View PDFchevron_right

The Effect of Bevacizumab on Vestibular Schwannoma Related to Neurofibromatosis Type 2

Michael Slancar

Australasian Journal of Neuroscience, 2021

View PDFchevron_right

Neurofibromatosis Type 2 (NF2) and the Implications for Vestibular Schwannoma and Meningioma Pathogenesis

Soma Sengupta

International Journal of Molecular Sciences, 2021

View PDFchevron_right

EANO Guideline on the Diagnosis and Treatment of Vestibular Schwannoma

Otologia Joan XXIII

View PDFchevron_right

Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas

Vanessa Merker

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016

View PDFchevron_right

Malignancy in a vestibular schwannoma. Report of a case with central neurofibromatosis, treated by both stereotactic radiosurgery and surgical excision, with a review of the literature

Andras Kemeny

British Journal of Neurosurgery, 2002

View PDFchevron_right

Clinical experience with gamma knife stereotactic radiosurgery in the management of vestibular schwannomas secondary to type 2 neurofibromatosis

Lee Walton

Journal of Neurology, Neurosurgery & Psychiatry, 2003

View PDFchevron_right

Neurofibromatosis type 2: case report

Tadeusz Mendel

Postepy Psychiatrii I Neurologii, 2013

View PDFchevron_right

Acoustic Neuroma (Vestibular Schwannoma) Revision

Richard Wiet

Otolaryngologic Clinics of North America, 2006

View PDFchevron_right

MRI based volumetric measurements of vestibular schwannomas in patients with neurofibromatosis type 2: comparison of three different software tools

Johannes A. Koeppen

Scientific Reports, 2020

View PDFchevron_right

Clinicopathologic Assay of 15 Tumor Resections in a Family with Neurofibromatosis Type 2

Gordana Juric-Sekhar

Journal of Neurological Surgery Part B: Skull Base, 2012

View PDFchevron_right

Hearing Improvement after Bevacizumab in Patients with Neurofibromatosis Type 2

Timothy Padera

New England Journal of Medicine, 2009

View PDFchevron_right

Metachronous Bilateral Vestibular Schwannomas

Renato Torres

The Laryngoscope, 2020

View PDFchevron_right

Stereotactic radiosurgery in the management of acoustic neuromas associated with neurofibromatosis Type 2

Brian Subach

Journal of Neurosurgery, 1999

View PDFchevron_right

Bevacizumab Therapy of Neurofibromatosis Type 2 Associated Vestibular Schwannoma in Japanese Patients

KENSHO IWATATE

Neurologia medico-chirurgica

View PDFchevron_right

First Place—Resident Clinical Science Award 1997: Germline screening of the NF-2 gene in families with unilateral vestibular schwannoma

Ali Surosh Attaie

Otolaryngology–Head and Neck Surgery, 1998

View PDFchevron_right

Bevacizumab decreases vestibular schwannomas growth rate in children and teenagers with neurofibromatosis type 2

Vianney Gaillard

Journal of Neuro-Oncology, 2015

View PDFchevron_right